Ministerial correction made by Will Quince (Conservative) on Tuesday, 21 February 2023, in the House of Commons on behalf of the Department of Health and Social Care.
Evusheld
The Government’s decision not to procure Evusheld at this time was based on independent clinical advice by the multi-agency RAPID C-19 and a United Kingdom national expert policy working group. RAPID C-19 . DHSC also sought advice from the a United Kingdom national expert policy working group, which includes a range of expertise including immunology, virology and relevant specialisms such as oncology. The membership of these groups also included experts in interpreting and analysing complex data, including clinicians and pharmacists, evidence assessors, and researchers.
- Corrected item
- Evusheld
Secondary information
- Type
- Written correction
- Session
- 2022-23
- Subjects
- Tixagevimab/cilgavimab
- Link
- View this Written correction on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-08-28 18:18:39 +0100
- URI
- http://data.parliament.uk/correction/commons/2022-23/67224
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/correction/commons/2022-23/67224
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/correction/commons/2022-23/67224